Research published on May 14 in the peer-reviewed journal Nature
Communications shows for the first time three distinct classifications
of sebaceous carcinoma, a rare and sometimes deadly form of skin cancer.
Company Website:
http://www.nantomics.com
CULVER CITY, Calif. -- (Business Wire)
NantOmics,
LLC, the leader in molecular analyses and a member of the NantWorks
ecosystem of companies, announced today the publication of peer-reviewed
research defining for the first time three distinct classifications of
sebaceous carcinoma, a rare and sometimes deadly former of skin cancer.
A study published on May 14 in the journal Nature
Communications shows that a signature analysis reveals three
clinically distinct classes of sebaceous carcinoma. The research offers
fresh insights into how to treat the disease and adds more data to the
concept that different mutational processes drive cancers that originate
in the same location but are clinically distinct.
Using the technology that drives NantHealth, Inc.’s (NASDAQ: NH) GPS
Cancer® platform, NantOmics scientists performed tumor-normal
DNA sequencing and RNA sequencing on tissue samples from 32 patients
with sebaceous carcinoma, revealing that the cell of origin and mutation
patterns defined three clinically distinct classes. These explain both
cancer ontogeny and clinical course.
“This is the first time that we have been able to define sebaceous
carcinoma into distinct molecular classifications with defined
mutational signature profiles,” said Dr. Shahrooz Rabizadeh, Chief
Scientific Officer at NantOmics. “We believe that our findings and the
classifications have significant implications on patient treatment.”
Dr. Patrick Soon-Shiong, CEO and founder of NantOmics, said the research
reiterated the importance of no longer treating cancer by anatomy, but
based on biology.
“This research has helped to decode signatures that are based on the
disease’s molecular profile,” Soon-Shiong said. “Beyond treatment
implications, this shows the absolute importance of looking at cancer
treatment from a biological perspective.”
Nature Communications is a peer-reviewed, open-access journal that
publishes research on all areas of natural sciences. Papers published by
the journal are considered to represent important advances in their
fields of research.
Other highlights from the paper:
-
A UV-damage signature classification predominates in ten of the 32
samples.
-
Nine of the samples are classified by microsatellite instability (MSI)
profiles, which has been shown to be responsive to and is approved for
pembrolizumab (Keytruda®) use.
-
The third classification, pauci-mutational sebaceous carcinoma has a
more varied signature, but half of which shared a similar mutation
pattern in ZNF750 transcription factor in this study.
-
Neoepitope analysis identified a subset of patients with highly clonal
mutation burden that may be most responsive to immunotherapy, and may
potentially be strong candidates for treatment with neoepitope
vaccines.
About NantOmics, LLC
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular analysis capabilities with the intent of providing actionable
intelligence and molecularly driven decision support for cancer patients
and their providers at the point of care. NantOmics is the first
molecular testing company to pioneer an integrated approach to
unearthing the genomic and proteomic variances that initiate and drive
cancer, by analyzing both normal and tumor cells from the same patient
and following identified variances through from DNA to RNA to protein to
drug. NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing genomic
variances in near real-time, and correlating proteomic pathway analysis
with quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissue and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system that integrates our unique
molecular profiling solution, software and hardware. Our system
infrastructure collects, indexes, analyzes and interprets billions of
molecular, clinical, operational and financial data points derived from
novel and traditional sources to continuously improve decision-making
and optimize our clinical pathways and decision algorithms over time.
For more information please visit http://www.nanthealth.com/.
About GPS Cancer®
GPS Cancer® is a unique, comprehensive test available through
NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing,
with enhanced expression analysis and bioinformatics of complex biologic
pathway systems, providing oncologists with a comprehensive molecular
profile of a patient’s cancer to inform personalized treatment
strategies. GPS Cancer testing is conducted in CLIA-certified and
CAP-accredited laboratories. For more information, visit www.gpscancer.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180521005846/en/
Contacts:
NANT MEDIA CONTACT
Jen Hodson
jhodson@nantworks.com
562-397-3639
or
Henry
Jackson
cj@nantworks.com
310-486-8908
Source: NantOmics, LLC
© 2024 Canjex Publishing Ltd. All rights reserved.